Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan:20:367-378.
doi: 10.1016/j.redox.2018.10.016. Epub 2018 Oct 25.

The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells

Affiliations

The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells

Ana Flórido et al. Redox Biol. 2019 Jan.

Abstract

Manganese(III) porphyrins (MnPs) are superoxide dismutase (SOD) mimics with demonstrated beneficial effects in cancer treatment in combination with chemo- and radiotherapy regimens. Despite the ongoing clinical trials, little is known about the effect of MnPs on metastasis, being therefore essential to understand how MnPs affect this process. In the present work, the impact of the MnP MnTnHex-2-PyP5+ in metastasis-related processes was assessed in breast cancer cells (MCF-7 and MDA-MB-231), alone or in combination with doxorubicin (dox). The co-treatment of cells with non-cytotoxic concentrations of MnP and dox altered intracellular ROS, increasing H2O2. While MnP alone did not modify cell migration, the co-exposure led to a reduction in collective cell migration and chemotaxis. In addition, the MnP reduced the dox-induced increase in random migration of MDA-MB-231 cells. Treatment with either MnP or dox decreased the proteolytic invasion of MDA-MB-231 cells, although the effect was more pronounced upon co-exposure with both compounds. Moreover, to explore the cellular mechanisms underlying the observed effects, cell adhesion, spreading, focal adhesions, and NF-κB activation were also studied. Although differential effects were observed according to the endpoints analysed, overall, the alterations induced by MnP in dox-treated cells were consistent with a therapeutically favorable outcome.

Keywords: Cancer; Cell invasion; Cell migration; Manganese porphyrins; Redox modulation; SOD mimics.

PubMed Disclaimer

Figures

fx1
Graphical abstract
Fig. 1
Fig. 1
Chemical structure of MnTnHex-2-PyP5+.
Fig. 2
Fig. 2
Treatment with MnP and low concentrations of dox does not induce cell death. MCF7 (A, C and E) and MDA-MB-231 (B, D and F) cell viability and cell death induction following exposure to the indicated MnP and dox concentrations, were evaluated by an MTT assay (A and B) and a DNA content assay after cell fixation (C-F), respectively. Histograms show representative MCF7 and MDA-MB-231 DNA content profiles following exposure to dox (0.1 μM), MnP (5 μM) or both, fixation and PI stain (C–D). Summary results from cell viability (A and B) and DNA content assays (E and F) are represented as means ± SD. PI, propidium iodide.
Fig. 3
Fig. 3
MnP and dox lead to an increase in intracellular ROS. Intracellular ROS levels were determined in MCF7 (A, B, C and E) or MDA-MB-231 (D and F) cells treated with the indicated drugs (dox (0.1 μM), MnP (5 μM)). Fluorescence microscopy images show representative MCF7 cells after 25-min incubation with DHR and DHE (A and B). Scale bars = 20 µm. Summary results (means ± SD from at least three independent experiments) show relative DHR and DHE fluorescence (C to F). *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Tukey's test, relative to untreated cells).
Fig. 4
Fig. 4
MnP and dox can reduce chemotaxis and random and collective cell migration. Collective cell migration, chemotaxis and random migration of MCF7 (A, C and F) or MDA-MB-231 (B, D and G) cells treated with the indicated drugs (dox (0.1 μM), MnP (5 μM)) were measured. Collective cell migration was measured by the wound healing assay (A and B), chemotaxis was measured using a transwell system with FBS as chemoattractant (C and D) and random cell migration on matrigel was measured using time lapse microscopy (F and G). Tracks of individual migrating cells (n = 60 for each condition) used to measure random cell migration are shown in E. Migration rates (A–D and F–G) are shown as means ± SD. *p < 0.05, **p < 0.01 (Student's t-test, relative to untreated cells).
Fig. 5
Fig. 5
Treatment with MnP and dox reduces MDA-MB-231 cell invasion and extracellular proteolytic activity. MDA-MB-231 cells were seeded on matrigel-coated transwells and were allowed to invade for 16 h in the presence of the indicated drugs (dox (0.1 μM), MnP (5 μM)) (A). The percentage of invading cells is summarized in B. The extracellular proteolytic activity was measured using a fluorescent gelatine degradation assay (C). Invasion rates (B), and normalized gelatine degradation (D) from at least three independent experiments are shown as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (Student's t-test, relative to untreated cells).
Fig. 6
Fig. 6
Co-treatment with MnP and dox increases cell area. MCF7 and MDA-MB-231 cell spread on matrigel was monitored over time (A and D). Cells treated with the indicated drugs for 16 h (B and E) or 30 min (C and F) were seeded on matrigel-coated transwells and allowed to spread. The cells were left to adhere for 12 h and cell area was measured. Data is summarized in B, C, E and F. Cell area determined from at least three independent experiments (n > 50 cells per condition and per experiment) and are shown as means ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Tukey's test, relative to untreated cells).
Fig. 7
Fig. 7
Effect of MnP and dox on the number of focal adhesions. Confocal images show MCF7 (A) and MDA-MB-231 (C) cells treated with the indicated drugs for 16 h, fixed and stained with anti pFAK. Images are typical of three independent experiments. Scale bars, 20 µm. Summary results (means ± SEM from ≥90 cells for each condition) show numbers of focal adhesions per cell, determined by counting pFAK positive spots (B and D). *p < 0.05, **p < 0.01 , ***p < 0.001 (one-way ANOVA with Tukey's test, relative to untreated cells).
Fig. 8
Fig. 8
Effect of MnP and dox treatment on the levels of FA proteins. Typical IB showing total pFAK, FAK, Paxillin and Vinculin and the loading controls (GAPDH and Tubulin) for MCF7 and MDA-MB-231 cells treated with the indicated drugs for 16 h (A). Summary results (means ± SD from three independent experiments) show relative protein expression levels for MCF7 cells (B) and MDA-MB-231 cells (C).
Fig. 9
Fig. 9
Effect of MnP and dox treatment on NF-κB-dependent transcription. MCF7 (A) and MDA-MB-231 (B) cells transfected with a firefly luciferase reporter plasmid under the control of an NF-κB-dependent promoter and a renilla luciferase transfection control were treated with the indicated drugs for 16 h. Data are from one experiment representative of at least three, each performed in 5 replicates are presented as means ± SD, *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA with Tukey's test), compared with untreated cells (-ve).

Similar articles

Cited by

References

    1. Batinic-Haberle I., Tovmasyan A., Spasojevic I. An educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins - from superoxide dismutation to H2O2-driven pathways. Redox Biol. 2015;5:43–65. - PMC - PubMed
    1. Batinić-Haberle I., Spasojevic I. Complex chemistry and biology of redox-active compounds, commonly known as SOD mimics, affect their therapeutic effects. Antioxid. Redox Signal. 2014;20:2323–2325. - PMC - PubMed
    1. Batinić-Haberle I., Rebouças J.S., Spasojević I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Signal. 2010;13:877–918. - PMC - PubMed
    1. Egea J., Fabregat I., Frapart Y.M., Ghezzi P., Görlach A., Kietzmann T., Kubaichuk K., Knaus U.G., Lopez M.G., Olaso-Gonzalez G., Petry A., Schulz R., Vina J., Winyard P., Abbas K., Ademowo O.S., Afonso C.B., Andreadou I., Antelmann H., Antunes F., Aslan M., Bachschmid M.M., Barbosa R.M., Belousov V., Berndt C., Bernlohr D., Bertrán E., Bindoli A., Bottari S.P., Brito P.M., Carrara G., Casas A.I., Chatzi A., Chondrogianni N., Conrad M., Cooke M.S., Costa J.G., Cuadrado A., My-Chan Dang P., De Smet B., Debelec–Butuner B., Dias I.H.K., Dunn J.D., Edson A.J., El Assar M., El-Benna J., Ferdinandy P., Fernandes A.S., Fladmark K.E., Förstermann U., Giniatullin R., Giricz Z., Görbe A., Griffiths H., Hampl V., Hanf A., Herget J., Hernansanz-Agustín P., Hillion M., Huang J., Ilikay S., Jansen-Dürr P., Jaquet V., Joles J.A., Kalyanaraman B., Kaminskyy D., Karbaschi M., Kleanthous M., Klotz L.-O., Korac B., Korkmaz K.S., Koziel R., Kračun D., Krause K.-H., Křen V., Krieg T., Laranjinha J., Lazou A., Li H., Martínez-Ruiz A., Matsui R., McBean G.J., Meredith S.P., Messens J., Miguel V., Mikhed Y., Milisav I., Milković L., Miranda-Vizuete A., Mojović M., Monsalve M., Mouthuy P.-A., Mulvey J., Münzel T., Muzykantov V., Nguyen I.T.N., Oelze M., Oliveira N.G., Palmeira C.M., Papaevgeniou N., Pavićević A., Pedre B., Peyrot F., Phylactides M., Pircalabioru G.G., Pitt A.R., Poulsen H.E., Prieto I., Rigobello M.P., Robledinos-Antón N., Rodríguez-Mañas L., Rolo A.P., Rousset F., Ruskovska T., Saraiva N., Sasson S., Schröder K., Semen K., Seredenina T., Shakirzyanova A., Smith G.L., Soldati T., Sousa B.C., Spickett C.M., Stancic A., Stasia M.J., Steinbrenner H., Stepanić V., Steven S., Tokatlidis K., Tuncay E., Turan B., Ursini F., Vacek J., Vajnerova O., Valentová K., Van Breusegem F., Varisli L., Veal E.A., Yalçın A.S., Yelisyeyeva O., Žarković N., Zatloukalová M., Zielonka J., Touyz R.M., Papapetropoulos A., Grune T., Lamas S., Schmidt H.H.H.W., Lisa F. Di, Daiber A. European contribution to the study of ROS: a summary of the findings and prospects for the future from the cost action BM1203 (EU-ROS) Redox Biol. 2017;13:94–162. - PMC - PubMed
    1. Fernandes A.S., Saraiva N., Oliveira N.G. Redox therapeutics in breast cancer: role of SOD mimics. In: Batinic-Haberle I., Reboucas J.S., Spasojevic I., editors. Redox-Active Therapeutics. 2016. pp. 451–467.

Publication types

MeSH terms